The global uncomplicated urinary tract infection treatment market trends is expected to increase at a compound annual growth rate (CAGR) of 10% between 2023 and 2033, from its 2022 valuation of US$ 5.96 billion to US$ 17 billion by 2023. A number of factors, such as the high frequency of UTIs, the rise in antibiotic resistance, and the growing awareness of the importance of treating UTIs appropriately, are driving the growth of the market for basic therapies for urinary tract infections. The UTI simple treatment market grew at a 5.7% compound annual growth rate (CAGR) from 2018 to 2022.
One of the key drivers of the market is the increasing awareness of UTIs. With the growing availability of information online and through social media, more and more people are becoming aware of the symptoms of UTIs and the importance of seeking prompt treatment. This is leading to higher demand for antibiotics and other treatments, driving growth in the market.
Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16923
Another factor driving the market is the growing geriatric population. As people age, their risk of developing UTIs increases, and with the world’s population aging rapidly, the demand for UTI treatments is also increasing. According to the United Nations, the number of people aged 65 and over is expected to triple by 2050, reaching nearly 1.5 billion.
Finally, the rising incidence of UTIs is also contributing to the growth of the market. Factors such as the growing prevalence of diabetes, changes in sexual behavior, and the increasing use of catheters and other medical devices are all leading to higher rates of UTIs. This is creating a growing demand for effective treatments that can quickly and safely clear up UTIs.
Key Takeaways from the Market Study
- The global Uncomplicated urinary tract infection treatment market is expected to grow with a 10% CAGR during 2023 to 2033.
- Retail pharmacies are expected to hold 47% of the market share in 2023 for Uncomplicated urinary tract infection treatment market.
- North America is expected to possess 48% market share for Uncomplicated urinary tract infection treatment market in 2023.
- Europe uncomplicated urinary tract infection treatment market size is expected to possess 40% market share in 2023.
- Retail Pharmacies Expected to Procure 47% Market Share for Uncomplicated Urinary Tract Infection Treatment Market: FMI Study
Key players are investing heavily in research and development to bring new and improved treatments to market, and are also working to expand their distribution networks to reach more patients.” states an FMI analyst
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16923
Competitive Landscape :
Key players in the uncomplicated urinary tract infection treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck & Co., Inc., Cipla Inc.
- GSK has developed a drug called Avycaz, which is a combination of ceftazidime and avibactam, used for the treatment of complicated UTIs. Avycaz is effective against a wide range of gram-negative bacteria, including some that are resistant to other antibiotics.
- Iterum Therapeutics is a biopharmaceutical company that is focusing on developing novel antibiotics to treat infections caused by multi-drug resistant pathogens, including those that cause Uncomplicated Urinary Tract Infections (UTIs).
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Uncomplicated urinary tract infection treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Drug Class (Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran) Distribution Channel (Hospital Pharmacies, Gynaecology and Urology Clinics, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Key Segments:
Drug Class:
- Gepotidacin
- Probenecid
- Sulfonamide
- Tetracycline
- Nitrofuran
Distribution Channel:
- Hospital Pharmacies
- Gynaecology and Urology Clinics
- Retail Pharmacies
- Online Drug Stores
Request Customization:https://www.futuremarketinsights.com/customization-available/rep-gb-16923
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
